8-K ·Filed Mar 4, 2026
8-K context-dependent: Items 5.02
Actionable Insight • Neutral
Monitor for any future disclosures regarding changes in executive compensation or strategic direction that may result from the expanded role. No trading action warranted based on this filing alone.
Final — all horizons settled through T+60d
VIR ▼ -0.77% at T+60d
NEUTRAL call ✗ call lost -0.77% · α vs SPY -12.07% · entry $9.10 → $9.03
T+1d
+4.95%
call +4.95% · α +6.26%
$9.55
settled 7mo ago
T+5d
+4.18%
call +4.18% · α +6.41%
$9.48
settled 7mo ago
T+20d
-0.44%
call -0.44% · α +3.35%
$9.06
settled 6mo ago
T+60d
-0.77%
call -0.77% · α -12.07%
$9.03
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Vir Biotechnology appointed CEO Marianne De Backer to the additional role of President. This is an internal leadership expansion with no immediate financial impact or executive departure.
Key Facts
- Marianne De Backer, current CEO and principal executive officer, was appointed to the additional role of President on March 4, 2026
- No executive departures were reported
- No compensation details were disclosed in the filing
- The appointment reflects a consolidation of leadership roles under the existing CEO
Financial Impact
No immediate financial impact disclosed
executive leadershipgovernance
Risk Factors
- Potential concentration of power in a single executive without checks and balances
- Lack of disclosed succession planning if De Backer holds both CEO and President roles
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-091447 |
| Document: 0001193125-26-091447-index-headers.html | 0001193125-26-091447 |
| Document: 0001193125-26-091447-index.html | 0001193125-26-091447 |
| Document: 0001193125-26-091447.txt | 0001193125-26-091447 |
18 reports for VIR
40% Hit rate best @ T+60▲ +10.12%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Court Ruling | $9.24 $9.78 | ▲ +5.84% | ▲ +7.21% | $11.17 (+20.89%) |
Aug 9, 2026 7w ago | Institutional Cluster | $8.89 $9.39 | ▲ +5.62% | ▲ +5.67% | $11.17 (+25.65%) |
Jul 24, 2026 10w ago | 8-K | $8.69 $8.90 | ▲ +2.42% | ▲ +2.04% | $11.17 (+28.54%) |
Jun 29, 2026 13w ago | 144 | $10.38 $10.02 | ▼ −3.47% | ▼ −4.86% | $11.17 (+7.61%) |
Jun 10, 2026 16w ago | 3 | $8.52 $9.30 | ▲ +9.15% | ▲ +8.72% | $11.17 (+31.10%) |
Jun 10, 2026 16w ago | 8-K | $8.52 $9.30 | ▲ +9.15% | ▲ +8.72% | $11.17 (+31.10%) |
Jun 2, 2026 17w ago | Insider Cluster | $8.77 $8.25 | ▼ −5.93% | ▼ −2.11% | $11.17 (+27.37%) |
May 28, 2026 18w ago | 8-K | $9.55 $8.77 | ▼ −8.17% | ▼ −8.12% | $11.17 (+16.96%) |
Apr 16, 2026 24w ago | DEFA14A | $10.33 $10.35 | ▲ +0.19% | ▼ −0.79% | $11.17 (+8.13%) |
Apr 10, 2026 25w ago | 8-K | $9.31 $11.09 | ▲ +19.12% | ▲ +15.82% | $11.17 (+19.98%) |
Showing 10 of 18
US Market Status
Market Closed — Opens Mon (64h 22m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access